Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1996 Mar;73(6):794–797. doi: 10.1038/bjc.1996.138

Experience with poorly myelosuppressive chemotherapy schedules for advanced myeloma. The Cooperative Group of Study and Treatment of Multiple Myeloma.

S Brugnatelli 1, A Riccardi 1, G Ucci 1, O Mora 1, L Barbarano 1, N Piva 1, L Piccinini 1, C Bergonzi 1, A De Paoli 1, M Di Stasi 1, E Rinaldi 1, G Trotti 1, M Petrini 1, E Ascari 1
PMCID: PMC2074366  PMID: 8611382

Abstract

In a multicentre study, 83 patients with advanced and previously uniformly treated multiple myeloma (MM) were randomised between cyclophosphamide (600 mg m-2) and epirubicin (70 mg m-2), administered every 3 weeks for three courses and both associated with prednisone and interferon-alpha2b. Both regimens were administered on an outpatient basis and had low haematological toxicity. Clinical results were similar. Overall response rate (43%) and median response and survival (5.9 and 14.1 months respectively) compare well with those obtained with more aggressive chemotherapy schedules.

Full text

PDF
794

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alberts D. S., Durie B. G., Salmon S. E. Doxorubicin/B.C.N.U. chemotherapy for multiple myeloma in relapse. Lancet. 1976 May 1;1(7966):926–928. doi: 10.1016/s0140-6736(76)92710-0. [DOI] [PubMed] [Google Scholar]
  2. Alexanian R., Barlogie B., Dixon D. High-dose glucocorticoid treatment of resistant myeloma. Ann Intern Med. 1986 Jul;105(1):8–11. doi: 10.7326/0003-4819-105-1-8. [DOI] [PubMed] [Google Scholar]
  3. Alexanian R., Dreicer R. Chemotherapy for multiple myeloma. Cancer. 1984 Feb 1;53(3):583–588. doi: 10.1002/1097-0142(19840201)53:3<583::aid-cncr2820530336>3.0.co;2-1. [DOI] [PubMed] [Google Scholar]
  4. Barlogie B., Alexanian R. Biology and therapy of multiple myeloma. Acta Haematol. 1987;78 (Suppl 1):171–174. doi: 10.1159/000205925. [DOI] [PubMed] [Google Scholar]
  5. Barlogie B., Hall R., Zander A., Dicke K., Alexanian R. High-dose melphalan with autologous bone marrow transplantation for multiple myeloma. Blood. 1986 May;67(5):1298–1301. [PubMed] [Google Scholar]
  6. Bergsagel D. E., Cowan D. H., Hasselback R. Plasma cell myeloma: response of melphalan-resistant patients to high-dose intermittent cyclophosphamide. Can Med Assoc J. 1972 Nov 4;107(9):851–855. [PMC free article] [PubMed] [Google Scholar]
  7. Bonnet J. D., Alexanian R., Salmon S. E., Haut A., Dixon D. O. Addition of cisplatin and bleomycin to vincristine-carmustine-doxorubicin-prednisone (VBAP) combination in the treatment of relapsing or resistant multiple myeloma: a Southwest Oncology Group study. Cancer Treat Rep. 1984 Mar;68(3):481–485. [PubMed] [Google Scholar]
  8. Brandes L. J., Israels L. G. Weekly low-dose cyclophosphamide and alternate-day prednisone: an effective low toxicity regimen for advanced myeloma. Eur J Haematol. 1987 Oct;39(4):362–368. doi: 10.1111/j.1600-0609.1987.tb00784.x. [DOI] [PubMed] [Google Scholar]
  9. Buzaid A. C., Durie B. G. Management of refractory myeloma: a review. J Clin Oncol. 1988 May;6(5):889–905. doi: 10.1200/JCO.1988.6.5.889. [DOI] [PubMed] [Google Scholar]
  10. Cohen H. J., Silberman H. R., Larsen W. E., Johnson L., Bartolucci A. A., Durant J. R. Combination chemotherapy with intermittent 1-3-bis(2-chloroethyl)1-nitrosourea (BCNU), cyclophosphamide, and prednisone for multiple myeloma. Blood. 1979 Oct;54(4):824–836. [PubMed] [Google Scholar]
  11. Cornelissen J. J., Sonneveld P., Schoester M., Raaijmakers H. G., Nieuwenhuis H. K., Dekker A. W., Lokhorst H. M. MDR-1 expression and response to vincristine, doxorubicin, and dexamethasone chemotherapy in multiple myeloma refractory to alkylating agents. J Clin Oncol. 1994 Jan;12(1):115–119. doi: 10.1200/JCO.1994.12.1.115. [DOI] [PubMed] [Google Scholar]
  12. Fermand J. P., Levy Y., Gerota J., Benbunan M., Cosset J. M., Castaigne S., Seligmann M., Brouet J. C. Treatment of aggressive multiple myeloma by high-dose chemotherapy and total body irradiation followed by blood stem cells autologous graft. Blood. 1989 Jan;73(1):20–23. [PubMed] [Google Scholar]
  13. Forgeson G. V., Selby P., Lakhani S., Zulian G., Viner C., Maitland J., McElwain T. J. Infused vincristine and adriamycin with high dose methylprednisolone (VAMP) in advanced previously treated multiple myeloma patients. Br J Cancer. 1988 Oct;58(4):469–473. doi: 10.1038/bjc.1988.243. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Friedenberg W. R., Kyle R. A., Knospe W. H., Bennett J. M., Tsiatis A. A., Oken M. M. High-dose dexamethasone for refractory or relapsing multiple myeloma. Am J Hematol. 1991 Mar;36(3):171–175. doi: 10.1002/ajh.2830360303. [DOI] [PubMed] [Google Scholar]
  15. Gimsing P., Bjerrum O. W., Brandt E., Ellegaard J., Evensen S. A., Hansen M. M., Hedenus M., Hippe E., Keldsen N., Palva I. Refractory myelomatosis treated with mitoxantrone in combination with vincristine and prednisone (NOP-regimen): a phase II study. The Nordic Myeloma Study Group (NMSG) Br J Haematol. 1991 Jan;77(1):73–79. doi: 10.1111/j.1365-2141.1991.tb07951.x. [DOI] [PubMed] [Google Scholar]
  16. Kyle R. A., Seligman B. R., Wallace H. J., Jr, Silver R. T., Glidewell O., Holland J. F. Mutiple myeloma resistant to melphalan (NSC-8806) treated with cyclophosphamide (NSC-26271), prednisone (NSC-10023), and chloroquine (NSC-187208). Cancer Chemother Rep. 1975 May-Jun;59(3):557–562. [PubMed] [Google Scholar]
  17. Lenhard R. E., Jr, Oken M. M., Barnes J. M., Humphrey R. L., Glick J. H., Silverstein M. N. High-dose cyclophosphamide. An effective treatment for advanced refractory multiple myeloma. Cancer. 1984 Apr 1;53(7):1456–1460. doi: 10.1002/1097-0142(19840401)53:7<1456::aid-cncr2820530705>3.0.co;2-c. [DOI] [PubMed] [Google Scholar]
  18. MacLennan I. C., Cusick J. Objective evaluation of the role of vincristine in induction and maintenance therapy for myelomatosis. Medical Research Council Working Party on Leukaemia in Adults. Br J Cancer. 1985 Aug;52(2):153–158. doi: 10.1038/bjc.1985.171. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Presant C. A., Klahr C. Adriamycin, 1,3-bis (2-chloroethyl) 1 nitrosourea (BCNU, NSC No. 409962), cyclophosphamide plus prednisone (ABC-P) in melphalanresistant multiple myeloma. Cancer. 1978 Sep;42(3):1222–1227. doi: 10.1002/1097-0142(197809)42:3<1222::aid-cncr2820420329>3.0.co;2-k. [DOI] [PubMed] [Google Scholar]
  20. Riccardi A., Ucci G., Luoni R., Brugnatelli S., Mora O., Spanedda R., De Paoli A., Barbarano L., Di Stasi M., Alberio F. Treatment of multiple myeloma according to the extension of the disease: a prospective, randomised study comparing a less with a more aggressive cystostatic policy. Cooperative Group of Study and Treatment of Multiple Myeloma. Br J Cancer. 1994 Dec;70(6):1203–1210. doi: 10.1038/bjc.1994.474. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Steinke B., Busch F. W., Becherer C., Ostendorf P., Waller H. D. Melphalan-resistant multiple myeloma: results of treatment according to the M-2 protocol. Cancer Chemother Pharmacol. 1985;14(3):279–281. doi: 10.1007/BF00258135. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES